[Federal Register Volume 82, Number 192 (Thursday, October 5, 2017)]
[Notices]
[Pages 46500-46501]
[FR Doc No: 2017-21494]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-D-4482]

Clarification of the Food and Drug Administration and
Environmental Protection Agency Jurisdiction Over Mosquito-Related
Products; Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a guidance for industry #236 entitled
``Clarification of FDA and EPA Jurisdiction Over Mosquito-Related
Products.'' This guidance provides information regarding regulatory
oversight of mosquito-related products, defined as those articles for
use in or on mosquitoes. We are clarifying circumstances under which
such products are regulated by the Food and Drug Administration (FDA)
as new animal drugs under the Federal Food, Drug, and Cosmetic Act (the
FD&C Act) and other circumstances under which such products are
regulated by the Environmental Protection Agency (EPA) as pesticides
under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).

DATES: The announcement of the guidance is published in the Federal
Register on October 5, 2017.

ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2016-D-4482 for ``Regulation of Mosquito-Related Products.''
Received comments will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access

the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    Submit written requests for single copies of the guidance to the
Policy and Regulations Staff (HFV-6), Center for Veterinary Medicine,
Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855.
Send one self-addressed adhesive label to assist that office in
processing your requests. See the SUPPLEMENTARY INFORMATION section for
electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT: Laura R. Epstein, Center for
Veterinary Medicine (HFV-1), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855,<PHONE_NUMBER>,
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Background

    In the Federal Register of January 19, 2017 (82 FR 6574), FDA
published the notice of availability for a draft guidance entitled
``Regulation of Mosquito-Related Products'' giving interested persons
until February 21, 2017, to comment on the draft guidance. FDA has
finalized that draft guidance and is issuing final guidance entitled
``Clarification of FDA and EPA Jurisdiction over Mosquito-Related
Products.'' This guidance provides information for industry and other
stakeholders regarding regulatory oversight of mosquito-related
products, defined as those articles for use in or on mosquitoes. Given
the public health implications of mosquito control, FDA is providing
this guidance to clarify the regulatory jurisdiction of mosquito-
related products, including but not limited to those produced through
biotechnology. This guidance is important in light of the public health
urgency of countering the spread of mosquito-borne disease, such as
that caused by the Zika virus. Vector control is a critical element of
the effort to combat the spread of mosquito-borne disease. Novel
mosquito control technologies have gained greater attention as an
element of this effort; however, there has been some confusion with
respect to FDA's and EPA's respective jurisdiction over such mosquito-
related products. We are clarifying circumstances under which such
products are regulated by FDA as new animal drugs under the FD&C Act
and other circumstances under which such products are regulated by EPA
as pesticides under FIFRA. FDA is clarifying that the phrase ``articles
(other than food) intended to affect the structure or any function of
the body of man or other animals'' in the FD&C Act's drug definition
(21 U.S.C. 321(g)(1)(C)) does not include articles intended to function
as pesticides by preventing, destroying, repelling, or mitigating
mosquitoes for population control purposes. FDA believes that this
interpretation is consistent with congressional intent and provides a
rational approach for dividing responsibilities between FDA and EPA in
regulating mosquito-related products.
    FDA received several comments on the draft guidance and those
comments were considered as the guidance was finalized. Some comments
on the draft guidance expressed confusion about how the intended use of
a product can determine whether a product is a drug or a pesticide. The
definition of ``drug'' in the FD&C Act depends upon the ``intended
use'' of a product. A product is a drug if it is intended to do certain
things (i.e., if it is ``intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease . . .'' and ``to affect
the structure or any function of the body . . .'' and for use as a
component of such a product. (21 U.S.C. 321(g)(1)). Even when
considering products subject only to the FD&C Act, the same product may
be classified differently depending on the intended use. For example,
an article that is intended to treat disease in an animal is an animal
drug, while the same article if intended to control mold growth in
animal feed could be a food additive (i.e., a substance ``the intended
use of which results . . . in its becoming a component or otherwise
affecting the characteristics of any food . . . if such substance is
not generally recognized among experts qualified by scientific training
and experience to evaluate its safety as having been adequately been
shown . . . to be safe. . . .''). Similarly, whether a product is a
``pesticide'' under FIFRA also depends upon intended use (``pesticide''
means, among other things, any substance or mixture of substances
intended for preventing, destroying, repelling, or mitigating any
pest). As a commenter pointed out, this means that the same product can
be a drug when intended for one use (i.e., diagnosing, curing,
mitigating, treating, or preventing disease) and a pesticide when
intended for another use (i.e., preventing, destroying, repelling, or
mitigating a pest). We have updated the guidance document in response
to these comments (see section III.C. of the guidance document). We
have also revised the title of the guidance document to better reflect
the scope of the document.

II. Significance of Guidance

    This level 1 guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The guidance represents
the current thinking of FDA on ``Clarification of FDA and EPA
Jurisdiction Over Mosquito-Related Products.'' It does not establish
any rights for any person and is not binding on FDA or the public. You
can use an alternative approach if it satisfies the requirements of the
applicable statutes and regulations. This guidance clarifies regulatory
jurisdiction and is not a significant regulatory action subject to
Executive Order 12866. Because FDA is clarifying that the definition of
``drug'' in the FD&C Act does not include articles intended to function
as pesticides by preventing, destroying, repelling, or mitigating
mosquitoes for population control purposes, it is a deregulatory action
on the part of FDA in that it clarifies that the manufacturers of such
articles will no longer be subject to FDA's regulatory jurisdiction.

III. Electronic Access

    Persons with access to the internet may obtain the guidance at
either https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm or
https://www.regulations.gov.

    Dated: October 2, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-21494 Filed 10-4-17; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register: June 2, 2010 (Volume 75, Number 105)]
[Notices]
[Page 30889-30890]
[DOCID:fr02jn10-142]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-62170; File No. SR-CBOE-2010-048]

Self-Regulatory Organizations; Chicago Board Options Exchange,
Incorporated; Notice of Filing and Immediate Effectiveness of Proposed
Rule Change To Permit CBOE To Open Short Term Option Series on
Thursdays

May 25, 2010.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(the ``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given
that on May 19, 2010, the Chicago Board Options Exchange, Incorporated
(``Exchange'' or ``CBOE'') filed with the Securities and Exchange
Commission (the ``Commission'') the proposed rule change as described
in Items I, II, and III below, which Items have been prepared by the
Exchange. The Exchange filed the proposal as a ``non-controversial''
proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act
\3\ and Rule 19b-4(f)(6) thereunder.\4\ The Commission is publishing
this notice to solicit comments on the proposed rule change from
interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \4\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    CBOE proposes to modify its rules to permit the Exchange, on any
Thursday or Friday, to open Short Term Option Series that expire on the
Friday of the following business week. The Exchange is not proposing
any rule text changes. The rule proposal is available on the Exchange's
Web site (http://www.cboe.org/legal), at the Exchange's Office of the
Secretary and at the Commission.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the self-regulatory organization
included statements concerning the purpose of and basis for the
proposed rule change and discussed any comments it received on the
proposed rule change. The text of those statements may be examined at
the places specified in Item IV below. The Exchange has prepared
summaries, set forth in sections A, B, and C below, of the most
significant parts of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Securities and Exchange Commission previously approved CBOE's
proposed rule change to permanently establish the Short Term Option
Series Pilot Program (``Program'').\5\ The Program allows CBOE to list
and trade equity and index option series that expire one week after
being opened for trading. Specifically, Rules 5.5(d) and 24.9 provide
that, after an option class has been approved for listing and trading
on the Exchange, the Exchange may open for trading on any Friday that
is a business day series of options on that class that expire on the
next Friday that is a business day.\6\ Under the Program, CBOE may
select up to five approved option classes on which Short Term Options
Series may be opened. The Exchange has selected the following four
option classes to participate in the Program: S&P 500 Index options
(SPX), S&P 100 Index American-style options (OEX), Mini-S&P 500 Index
options (XSP), and S&P 100 Index European-style options (XEO).
---------------------------------------------------------------------------

    \5\ See Securities Exchange Act Release No. 59824 (April 27,
2009), 74 FR 20518 (May 4, 2009) (SR-CBOE-2009-018).
    \6\ If the Exchange is not open for business on a Friday, the
Short Term Opening Date will be the first business day immediately
prior to that Friday. Similarly if the Exchange is not open for
business on a Friday, the Short Term Option Expiration Date will be
the first business day immediately prior to that Friday.
---------------------------------------------------------------------------

    The purpose of this filing is to permit the Exchange to open Short
Term Option Series on any Thursday (or Friday) that expire on the
Friday of the following business week. In support of this modification,
the Exchange states that it has received requests to begin certain
Short Term Options on Thursday so that market participants may have an
opportunity to ``roll'' expiring positions; that is, trade out of an
expiring Short Term Option Series and re-establish a new position in
Short Term Option Series expiring one week later. Since the last
trading day for A.M.-settled Short Term Options on indexes is generally
a Thursday, and new A.M.-settled Short Term Option Series on indexes
are generally listed on Friday, new and expiring A.M.-settled Short
Term Option Series on indexes are never available concurrently.
    As a result, it is impossible to implement a position roll in A.M.-
settled Short Term Options on indexes. The Exchange has been advised
that opening A.M.-settled Short Term Options on indexes just one day
earlier, and providing an opportunity to roll, would enhance the value
A.M.-settled Short Term Options on indexes as a risk management tool.
    In order to avoid investor confusion, the Exchange is proposing to
permit the listing of all Short Term Option series (equity and index)
on any Thursday or Friday. As proposed, the rule changes give the
Exchange the flexibility to list Short Term Option series on any
Thursday or Friday, and do not restrict listing to a particular day.
2. Statutory Basis
    The Exchange believes this rule proposal is consistent with the Act
and the rules and regulations under the Act applicable to a national
securities exchange and, in particular, the requirements of Section
6(b) of the Act.\7\ Specifically, the Exchange believes that the
proposed rule change is consistent with the Section 6(b)(5) Act \8\
requirements that the rules of an exchange be designed to promote just
and equitable principles of trade, to prevent fraudulent and
manipulative acts and, in general, to protect investors and the public
interest. In particular, the

proposed rule change will benefit market participants by allowing them
to more closely manage their risk exposures and carry out their
investment objectives.
---------------------------------------------------------------------------

    \7\ 15 U.S.C. 78f(b).
    \8\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    CBOE does not believe that the proposed rule change will impose any
burden on competition not necessary or appropriate in furtherance of
the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    No written comments were solicited or received with respect to the
proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule does not (i) significantly
affect the protection of investors or the public interest; (ii) impose
any significant burden on competition; and (iii) become operative for
30 days from the date on which it was filed, or such shorter time as
the Commission may designate if consistent with the protection of
investors and the public interest, provided that the self-regulatory
organization has given the Commission written notice of its intent to
file the proposed rule change at least five business days prior to the
date of filing of the proposed rule change or such shorter time as
designated by the Commission, the proposed rule change has become
effective pursuant to Section 19(b)(3)(A) of the Act \9\ and Rule 19b-
4(f)(6) thereunder.\10\ At any time within 60 days of the filing of
such proposed rule change, the Commission may summarily abrogate such
rule change if it appears to the Commission that such action is
necessary or appropriate in the public interest, for the protection of
investors, or otherwise in furtherance of the purposes of the Act.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78s(b)(3)(A).
    \10\ 17 CFR 240.19b-4(f)(6). Rule 19b-4(f)(6)(iii) requires the
self-regulatory organization to submit to the Commission written
notice of its intent to file the proposed rule change, along with a
brief description and text of the proposed rule change, at least
five business days prior to the date of filing of the proposed rule
change, or such shorter time as designated by the Commission. The
Exchange has satisfied this requirement.
---------------------------------------------------------------------------

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://
www.sec.gov/rules/sro.shtml); or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-CBOE-2010-048 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-CBOE-2010-048. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/
sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for Web site viewing and
printing in the Commission's Public Reference Room, 100 F Street, NE.,
Washington, DC 20549, on official business days between the hours of 10
a.m. and 3 p.m. Copies of the filing also will be available for
inspection and copying at the principal office of the Exchange. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-CBOE-2010-048 and should be
submitted on or before June 23, 2010.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\11\
---------------------------------------------------------------------------

    \11\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
[FR Doc. 2010-13160 Filed 6-1-10; 8:45 am]
BILLING CODE 8010-01-P


[Federal Register Volume 84, Number 228 (Tuesday, November 26, 2019)]
[Notices]
[Pages 65150-65151]
[FR Doc No: 2019-25628]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings #1

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER20-413-000.
    Applicants: CalPeak Power--Vaca Dixon LLC.
    Description: Sec.  205(d) Rate Filing: Normal 2019 to be effective
11/20/2019.
    Filed Date: 11/19/19.
    Accession Number: 20191119-5128.
    Comments Due: 5 p.m. ET 12/10/19.

    Docket Numbers: ER20-414-000.
    Applicants: CalPeak Power--Enterprise LLC.
    Description: Sec.  205(d) Rate Filing: Normal 2019 to be effective
11/20/2019.
    Filed Date: 11/19/19.
    Accession Number: 20191119-5130.
    Comments Due: 5 p.m. ET 12/10/19.

    Docket Numbers: ER20-415-000.
    Applicants: CalPeak Power--Panoche LLC.
    Description: Sec.  205(d) Rate Filing: Normal 2019 to be effective
11/20/2019.
    Filed Date: 11/19/19.
    Accession Number: 20191119-5134.
    Comments Due: 5 p.m. ET 12/10/19.

    Docket Numbers: ER20-416-000.
    Applicants: Southwest Power Pool, Inc.
    Description: Sec.  205(d) Rate Filing: 2827R5 KPP and Evergy Kansas
Central Meter Agent Agreement to be effective 11/1/2019.
    Filed Date: 11/19/19.
    Accession Number: 20191119-5141.
    Comments Due: 5 p.m. ET 12/10/19.

    Docket Numbers: ER20-417-000.
    Applicants: Southwest Power Pool, Inc.
    Description: Sec.  205(d) Rate Filing: 2855R5 KMEA and Evergy Metro
Meter Agent Agreement to be effective 11/1/2019.
    Filed Date: 11/19/19.
    Accession Number: 20191119-5145.
    Comments Due: 5 p.m. ET 12/10/19.

    Docket Numbers: ER20-418-000.
    Applicants: Southwest Power Pool, Inc.
    Description: Sec.  205(d) Rate Filing: Revisions to Unbundle
Schedule 1-A Tariff Administration Services to be effective 1/1/2021.
    Filed Date: 11/19/19.
    Accession Number: 20191119-5149.
    Comments Due: 5 p.m. ET 12/10/19.

    Docket Numbers: ER20-419-000.
    Applicants: ITC Midwest LLC.
    Description: Sec.  205(d) Rate Filing: Filing of CIAC Agreement
with Northern States to be effective 1/19/2020.
    Filed Date: 11/19/19.
    Accession Number: 20191119-5150.
    Comments Due: 5 p.m. ET 12/10/19.

    Docket Numbers: ER20-420-000.
    Applicants: Midcontinent Independent System Operator, Inc.
    Description: Sec.  205(d) Rate Filing: 2019-11-20_SA 3375 Entergy
Arkansas-Searcy Solar GIA (J893) to be effective 11/5/2019.
    Filed Date: 11/20/19.
    Accession Number: 20191120-5005.
    Comments Due: 5 p.m. ET 12/11/19.

    Docket Numbers: ER20-421-000.
    Applicants: Montana-Dakota Utilities Co.
    Description: Compliance filing: Compliance Filing to Revise Montana
Dakota Utilities Market Based Rate Tariff to be effective 10/31/2019.
    Filed Date: 11/20/19.
    Accession Number: 20191120-5029.
    Comments Due: 5 p.m. ET 12/11/19.

    Docket Numbers: ER20-422-000.
    Applicants: FL Solar 1, LLC.
    Description: Baseline eTariff Filing: Application for Market Based
Rate to be effective 11/21/2019.
    Filed Date: 11/20/19.
    Accession Number: 20191120-5037.
    Comments Due: 5 p.m. ET 12/11/19.

    Docket Numbers: ER20-423-000.
    Applicants: Energy Unlimited, Inc.
    Description: Tariff Cancellation: Energy Unlimited, Inc. Notice of
Cancellation to be effective 12/1/2019.
    Filed Date: 11/20/19.
    Accession Number: 20191120-5060.
    Comments Due: 5 p.m. ET 12/11/19.

    Docket Numbers: ER20-424-000.
    Applicants: Midcontinent Independent System Operator, Inc.
    Description: Sec.  205(d) Rate Filing: 2019-11-20_SA 1212 ITC
Midwest-FPL Energy 2nd Rev GIA (G056) to be effective 11/4/2019.
    Filed Date: 11/20/19.
    Accession Number: 20191120-5071.
    Comments Due: 5 p.m. ET 12/11/19.

    Docket Numbers: ER20-425-000.
    Applicants: American Municipal Power, Inc.
    Description: Compliance filing: EL18-181 eTariff Settlement
Compliance Filing to be effective 7/1/2018.
    Filed Date: 11/20/19.
    Accession Number: 20191120-5075.
    Comments Due: 5 p.m. ET 12/11/19.

    Docket Numbers: ER20-426-000.
    Applicants: Energy Alternatives Wholesale, LLC.
    Description: Tariff Cancellation: Notice of Cancellation to be
effective 11/21/2019.
    Filed Date: 11/20/19.
    Accession Number: 20191120-5096.
    Comments Due: 5 p.m. ET 12/11/19.

    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's

Regulations (18 CFR 385.211 and 385.214) on or before 5:00 p.m. Eastern
time on the specified comment date. Protests may be considered, but
intervention is necessary to become a party to the proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: November 20, 2019.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2019-25628 Filed 11-25-19; 8:45 am]
 BILLING CODE 6717-01-P